Articles From: Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015 to Alibaba Group Announces Proposed Offering of Senior Unsecured Notes


Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned retirement of company co-founder Stephen Squinto, Ph.D., effective January 1, 2015.
Sign-up for Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015 investment picks
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.
Sign-up for Alexion Completes Rolling BLA Submission to U.S. FDA for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Every Day with HPP ™ campaign in support of the third annual Hypophosphatasia (HPP) Awareness Week Oct.
Sign-up for Alexion Launches Every Day with HPP™ Campaign in Support of Hypophosphatasia (HPP) Awareness Week investment picks
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2014 on Thursday, January 29, 2015 before the US financial markets open.
Sign-up for Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015 investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today reported results from its randomized, open-label, multicenter Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living-donor kidney transplant recipients requiring desensitization.
Sign-up for Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the three and nine months ended September 30, 2014.
Sign-up for Alexion Reports Third Quarter 2014 Results investment picks
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the J.P. Morgan 33 rd Annual Healthcare Conference in San Francisco on Monday, January 12, 2015 at 10:30 a.m., PT (1:30 p.m., ET). An audio webcast of the presentation will be available live.
Sign-up for Alexion to Present at the J.P. Morgan 33rd Annual Healthcare Conference investment picks
By Russ Britt, MarketWatch Treatment designed to help kidney patients accept new organs Shares of Alexion Pharmaceuticals Inc. fell in after-hours trades after the drug maker said its plan to use its Soliris blood-clotting treatment to help kidney transplant patients accept their new organ didn't meet its goals in the second phase of testing.
Sign-up for Alexion tumbles on failed transplant drug trial investment picks
Alexion Pharmaceuticals Inc. (ALXN) said a clinical trial of its blood-clotting drug Soliris used to treat kidney transplant recipients failed to meet its goals.
Sign-up for Alexion's Kidney Transplant Drug Soliris Fails Trial investment picks
By Maria Armental Alexion Pharmaceuticals Inc. (ALXN) said a clinical trial of its blood-clotting drug Soliris used to treat kidney transplant recipients failed to meet its goals.
Sign-up for Alexion's Kidney Transplant Drug Soliris Fails Trial investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE® investment picks
Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential Milestone Payments MOUNTAIN VIEW, Calif.
Sign-up for Alexza and Ferrer Expand ADASUVE® Partnership investment picks
MOUNTAIN VIEW, Calif.
Sign-up for Alexza Pharmaceuticals Announces Presentation at Stifel 2014 Healthcare Conference investment picks
2014/11/5
Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif.
Sign-up for Alexza Reports 2014 Third Quarter Financial Results investment picks
2014/12/5
http://media.marketwire.com/attachments/201412/TN-295075_02100805122014-1333156867HIPH_ART_BASEL.001.jpeg.jpg Adriana De Moura is on the front and back cover of Design District Magazines 'Art Basel Issue' http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163425&ProfileId=051205&sourceType=1 MIAMI BEACH, FL --
Sign-up for Alfred Culbreth Announces the Amazing Adriana De Moura Does Art Basel L'Alpina Style; Alfred Culbreth Is CEO of American Premium Water Corporation (OTC: HIPH) investment picks
OAKVILLE, ON , Nov.
Sign-up for Algonquin Power & Utilities Corp. Announces 2014 Third Quarter Financial Results investment picks
OAKVILLE, ON , Nov.
Sign-up for Algonquin Power & Utilities Corp. announces additional 10MW solar generation project investment picks
2014/11/13
OAKVILLE, ON , Nov.
Sign-up for Algonquin Power & Utilities Corp. Declares Fourth Quarter 2014 Dividends investment picks
OAKVILLE, ON , Nov.
Sign-up for Algonquin Power & Utilities Corp. to Partner with Kinder Morgan investment picks
2014/11/5
By Jennifer Booton, MarketWatch NEW YORK (MarketWatch) -- Alibaba Group's rising costs are nothing to worry about, analysts said Wednesday upon issuing a wave of bullish notes on the company.
Sign-up for Alibaba analysts shrug off high costs investment picks
2014/11/16
By Qu Yunxu BEIJING (Caixin Online) -- Alibaba Group Holding Ltd.'s (BABA) annual e-commerce frenzy smashed last year's record, but company executives were not exactly ecstatic.
Sign-up for Alibaba and the truth behind the Singles Day sales numbers investment picks
2015/1/13
By Gillian Wong HONG KONG-- Alibaba Group Holding said Wednesday it has bought a controlling stake in a Chinese Internet marketing firm in a move aimed at expanding its advertising business.
Sign-up for Alibaba Buys Controlling Stake in Chinese Internet Marketing Firm investment picks
Alibaba Group Holding Inc. (BABA) CEO Jack Ma said in an interview with CNBC that he plans to take the company's payments arm, Alipay, public.
Sign-up for Alibaba CEO: Alipay ready to explore IPO investment picks
By Rex Crum, MarketWatch SAN FRANCISCO (MarketWatch) -- Tech stocks showed signs of shaking off their early doldrums Wednesday, with many sector leaders managing to eke out mild gains in the wake of the midterm elections in the U.S. Among tech sector leaders, mild gains came from Oracle Corp.
Sign-up for Alibaba gains, but TripAdvisor weighs on tech investment picks
Three analysts initiated coverage on Alibaba Group (BABA) with bullish ratings on Wednesday, as a 40-day quiet period on Alibaba's IPO underwriters expired.
Sign-up for Alibaba gets bullish ratings from IPO underwriters investment picks
Alibaba Group Holding Limited (NYSE: BABA) today announced that it proposes to offer senior unsecured notes (the "notes"), subject to market and other conditions.
Sign-up for Alibaba Group Announces Proposed Offering of Senior Unsecured Notes investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Alexion Announces Planned Retirement of Stephen Squinto, Ph.D., Company Co-Founder and Chief Global Operations Officer, in January 2015 to Alibaba Group Announces Proposed Offering of Senior Unsecured Notes
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent